Sökning: onr:"swepub:oai:DiVA.org:uu-358199" > Autologous Transpla...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 08161naa a2200841 4500 | |
001 | oai:DiVA.org:uu-358199 | |
003 | SwePub | |
008 | 180831s2018 | |||||||||||000 ||eng| | |
009 | oai:prod.swepub.kib.ki.se:138548517 | |
024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-3581992 URI |
024 | 7 | a https://doi.org/10.1016/j.bbmt.2017.12.7712 DOI |
024 | 7 | a http://kipublications.ki.se/Default.aspx?queryparsed=id:1385485172 URI |
040 | a (SwePub)uud (SwePub)ki | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a ref2 swepub-contenttype |
072 | 7 | a art2 swepub-publicationtype |
100 | 1 | a Casulo, Carlau Univ Rochester, Wilmot Canc Inst, New York, NY USA4 aut |
245 | 1 0 | a Autologous Transplantation in Follicular Lymphoma with Early Therapy Failure :b A National LymphoCare Study and Center for International Blood and Marrow Transplant Research Analysis |
264 | 1 | b Elsevier BV,c 2018 |
338 | a print2 rdacarrier | |
520 | a Patients with follicular lymphoma (FL) experiencing early therapy failure (ETF) within 2 years of frontline chemoimmunotherapy have poor overall survival (OS). We analyzed data from the Center for International Blood and Marrow Transplant Research (CIBMTR) and the National LymphoCare Study (NLCS) to determine whether autologous hematopoietic cell transplant (autoHCT) can improve outcomes in this high-risk FL subgroup. ETF was defined as failure to achieve at least partial response after frontline chemoimmunotherapy or lymphoma progression within 2 years of frontline chemoimmunotherapy. We identified 2 groups: the non-autoHCT cohort (patients from the NLCS with ETF not undergoing autoHCT) and the autoHCT cohort (CIBMTR patients with ETF undergoing autoHCT). All patients received rituximab-based chemotherapy as frontline treatment; 174 non-autoHCT patients and 175 autoHCT patients were identified and analyzed. There was no difference in 5-year OS between the 2 groups (60% versus 67%, respectively; P = .16). A planned subgroup analysis showed that patients with ETF receiving autoHCT soon after treatment failure (≤1 year of ETF; n = 123) had higher 5-year OS than those without autoHCT (73% versus 60%, P = .05). On multivariate analysis, early use of autoHCT was associated with significantly reduced mortality (hazard ratio, .63; 95% confidence interval, .42 to .94; P = .02). Patients with FL experiencing ETF after frontline chemoimmunotherapy lack optimal therapy. We demonstrate improved OS when receiving autoHCT within 1 year of treatment failure. Results from this unique collaboration between the NLCS and CIBMTR support consideration of early consolidation with autoHCT in select FL patients experiencing ETF. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Hematologi0 (SwePub)302022 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Hematology0 (SwePub)302022 hsv//eng |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng |
653 | a Follicular lymphoma | |
653 | a Early therapy failure | |
653 | a Autologous transplantation | |
653 | a Early transplant | |
653 | a Rituximab | |
653 | a Chemoimmunotherapy | |
700 | 1 | a Friedberg, Jonathan W.u Univ Rochester, Wilmot Canc Inst, New York, NY USA4 aut |
700 | 1 | a Ahn, Kwang W.u Med Coll Wisconsin, Ctr Int Blood & Marrow Transplant Res, Dept Med, Milwaukee, WI 53226 USA;Med Coll Wisconsin, Inst Hlth & Soc, Div Biostat, Milwaukee, WI 53226 USA4 aut |
700 | 1 | a Flowers, Christopheru Emory Univ, Winship Canc Inst, Dept Hematol & Med Oncol, Sch Med, Atlanta, GA 30322 USA4 aut |
700 | 1 | a DiGilio, Alyssau Med Coll Wisconsin, Ctr Int Blood & Marrow Transplant Res, Dept Med, Milwaukee, WI 53226 USA4 aut |
700 | 1 | a Smith, Sonali M.u Univ Chicago, Sect Hematol Oncol, Chicago, IL 60637 USA4 aut |
700 | 1 | a Ahmed, Sairahu Univ MD Anderson Canc Ctr, Dept Stem Cell Transplantat, Div Canc Med, Houston, TX USA4 aut |
700 | 1 | a Inwards, Davidu Mayo Clin, Div Hematol, Rochester, MN USA4 aut |
700 | 1 | a Aljurf, Mahmoudu King Faisal Specialist Hosp Ctr & Res, Dept Oncol, Riydah, Saudi Arabia4 aut |
700 | 1 | a Chen, Andy, Iu Oregon Hlth & Sci Univ, Blood & Marrow Transplant Program, Portland, OR 97201 USA4 aut |
700 | 1 | a Choe, Hannahu Weill Cornell Med Coll, Blood & Marrow Transplant Program, New York, NY USA4 aut |
700 | 1 | a Cohen, Jonathonu Emory Univ, Winship Canc Inst, Dept Hematol & Med Oncol, Sch Med, Atlanta, GA 30322 USA4 aut |
700 | 1 | a Copelan, Edwardu Carolinas HealthCare Syst, Dept Hematol Oncol & Blood Disorders, Levine Canc Inst, Charlotte, NC USA4 aut |
700 | 1 | a Farooq, Umaru Univ Iowa, Dept Med, Iowa City, IA 52242 USA4 aut |
700 | 1 | a Fenske, Timothy S.u Med Coll Wisconsin, Dept Med, Div Hematol & Oncol, Milwaukee, WI 53226 USA4 aut |
700 | 1 | a Freytes, Cesaru Texas Transplant Inst, Blood & Marrow Transplant Program, San Antonio, TX USA4 aut |
700 | 1 | a Gaballa, Samehu Thomas Jefferson Univ Hosp, Blood & Marrow Transplant Program, Philadelphia, PA 19107 USA4 aut |
700 | 1 | a Ganguly, Siddharthau Univ Kansas, Div Hematol Malignancies & Cellular Therapeut, Med Ctr, Kansas City, KS 66103 USA4 aut |
700 | 1 | a Jethava, Yogeshu Univ Arkansas Med Sci, Blood & Marrow Transplant Program, Little Rock, AR 72205 USA4 aut |
700 | 1 | a Kamble, Rammurti T.u Baylor Coll Med, Ctr Cell & Gene Therapy, Div Hematol & Oncol, Houston, TX 77030 USA4 aut |
700 | 1 | a Kenkre, Vaishalee P.u Univ Wisconsin, Div Hematol & Oncol, Madison, WI USA4 aut |
700 | 1 | a Lazarus, Hillardu Univ Hosp Cleveland, Seidman Canc Ctr, Med Ctr, Cleveland, OH 44106 USA4 aut |
700 | 1 | a Lazaryan, Aleksandru Univ Minnesota, Blood & Marrow Transplant Program, Minneapolis, MN USA4 aut |
700 | 1 | a Olsson, Richardu Karolinska Institutet,Uppsala universitet,Centrum för klinisk forskning i Sörmland (CKFD),Karolinska Inst, Dept Lab Med, Div Therapeut Immunol, Stockholm, Sweden4 aut0 (Swepub:uu)riols677 |
700 | 1 | a Rezvani, Andrew R.u Stanford Hlth Care, Blood & Marrow Transplant Program, Stanford, CA USA4 aut |
700 | 1 | a Rizzieri, Davidu Duke Univ, Div Hematol Malignancies & Cellular Therapy, Durham, NC USA4 aut |
700 | 1 | a Seo, Sachikou East Hosp, Natl Canc Res Ctr, Chiba, Japan4 aut |
700 | 1 | a Shah, Gunjan L.u Mem Sloan Kettering Canc Ctr, Blood & Marrow Transplant Program, 1275 York Ave, New York, NY 10021 USA4 aut |
700 | 1 | a Shah, Ninau Univ MD Anderson Canc Ctr, Dept Stem Cell Transplantat, Div Canc Med, Houston, TX USA4 aut |
700 | 1 | a Solh, Melhamu Northside Hosp, Blood & Marrow Transplant Grp Georgia, Atlanta, GA USA4 aut |
700 | 1 | a Sureda, Annau Inst Catala Oncol Hosp, Hematol Dept, Barcelona, Spain4 aut |
700 | 1 | a William, Basemu Ohio State Med Ctr, James Canc Ctr, Columbus, OH USA4 aut |
700 | 1 | a Cumpston, Aaronu West Virginia Univ Hosp, Blood & Marrow Transplant Program, Morgantown, WV USA4 aut |
700 | 1 | a Zelenetz, Andrew D.u Mem Sloan Kettering Canc Ctr, Blood & Marrow Transplant Program, 1275 York Ave, New York, NY 10021 USA4 aut |
700 | 1 | a Link, Brian K.u Med Coll Wisconsin, Dept Med, Div Hematol & Oncol, Milwaukee, WI 53226 USA4 aut |
700 | 1 | a Hamadani, Mehdiu Med Coll Wisconsin, Ctr Int Blood & Marrow Transplant Res, Dept Med, Milwaukee, WI 53226 USA4 aut |
710 | 2 | a Univ Rochester, Wilmot Canc Inst, New York, NY USAb Med Coll Wisconsin, Ctr Int Blood & Marrow Transplant Res, Dept Med, Milwaukee, WI 53226 USA;Med Coll Wisconsin, Inst Hlth & Soc, Div Biostat, Milwaukee, WI 53226 USA4 org |
773 | 0 | t Biology of blood and marrow transplantationd : Elsevier BVg 24:6, s. 1163-1171q 24:6<1163-1171x 1083-8791x 1523-6536 |
856 | 4 | u http://www.bbmt.org/article/S1083879117316750/pdf |
856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-358199 |
856 | 4 8 | u https://doi.org/10.1016/j.bbmt.2017.12.771 |
856 | 4 8 | u http://kipublications.ki.se/Default.aspx?queryparsed=id:138548517 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
Kopiera och spara länken för att återkomma till aktuell vy